Royalty Report: Drugs, Ophthalmological, Pharmaceuticals – Collection: 27999


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Ophthalmological
  • Pharmaceuticals
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27999

License Grant
The Agreement with the Licensee is structured so that the Licensor receives consideration based on its adjusted gross profit from its sales of Silicone Oil on a quarterly basis.
License Property
The Licensor operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of ophthalmic medical devices, ophthalmic pharmaceuticals and vascular devices.

Silicone oil is indicated for use as a prolonged retinal tamponade in selected cases of complicated retinal detachments when other interventions are not appropriate for patient management. Complicated retinal detachments or recurrent retinal detachments occur most commonly following perforating injuries or in eyes with proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy (PDR), cytomegalovirus (CMV) retinitis, or giant tears.
—Silicone oil is also indicated in the treatment of retinal detachments due to acquired immunodeficiency syndrome (AIDS)-related CMV retinitis and other viral infections.

Field of Use
Silicone Oils are insoluble in aqueous fluid and allow maintenance of retinal positioning for extended periods.

IPSCIO Record ID: 26094

License Grant
The Licensor hereby granted to the Licensee a royalty-bearing, exclusive worldwide right and license, with the right to grant sublicenses, for Cytokine Modulator (CM) as a therapeutic drug containing a single active pharmaceutical ingredient or two or more active pharmaceutical ingredients where no component of the CM is tacrolimus, cyclosporine, ISAtx24, Rapamycin (Sirolimus), Pimecrolimus, Everolimus, another calcineurin inhibitor or a corticosteroid. Subject to the terms and conditions of this Agreement, the Licensor shall grant the Licensee a right of reference to the Licensor Generated Data to Exploit Licensed Products in the Licensed Combination Field.
License Property
BOE Disease means the following diseases Wet Age-related Macular Degeneration; Dry Age-related Macular Degeneration; Posterior uveitis (chorioentinitis); Retinitis Pigmentosa; Retinal Vein Occlusion; Retinal detachment; Retinal Artery Occlusion; Proliferative diabetic retinopathy; Post-operative inflammation; Persistant Macular Edema; Neovascular diseases involving the retina or uveal tract such as neovascular glaucoma, neovascularization following a combined vitrectomy and lensectomy, neovascularization of the optic nerve, and neovascularization due to penetration of the eye or contusive ocular injury; Inflammation due to ocular trauma; Open-angle glaucoma; Closed-angle glaucoma; Exudative macular edema; Diabetic Retinopathy; Diabetic Macular Edema; Cystoid macular edema; Chronic posterior uveitis; Allograft rejection; Behcet's syndrome; Chorioiditis; Crystalline retinopathy; Optic neurtitis; Proliferative sickle cell retinopathy; Proliferative vitreoretinopathy; Retinopathy of prematurity; Vitreitis; Temporal arteritis; Fuchs' Dystrophy; Dacryocystitis; Giant cell arteritis; Sympathetic ophthalmia; Pars planitis; Pan Uveitis; and all other similar diseases as agreed to by the Parties.
Field of Use
Licensee has certain proprietary in vitro and in vivo models of ophthalmic diseases, and clinical expertise in developing ophthalmic therapeutics.  Collaboration Combination Field means use of a Collaboration Combination by Local Administration to treat the diseases.

IPSCIO Record ID: 2377

License Grant
The Company hereby grants to the Licensee exclusive rights to register, import, market, sell and distribute the Products in the Territory.
License Property
The Company has developed among other things certain proprietary technology relating to non-surgical therapeutic ophthalmic systems

Products refers to Vitrase(TM) and Corneaplasty, certain proprietary technology relating to non-surgical therapeutic ophthalmic systems.

We are developing Vitrase, a proprietary formulation of hyaluronidase, for treatment of severe vitreous hemorrhage, a sight threatening condition, and diabetic retinopathy, the leading cause of adult blindness in the United States.  Vitrase is currently in two Phase III clinical trials for treatment of severe vitreous hemorrhage. We are also conducting a pilot Phase IIa clinical trial of Vitrase in Mexico for treatment of diabetic retinopathy.  Vitreous hemorrhage.  A vitreous hemorrhage occurs when retinal blood vessels rupture and bleed into the vitreous humor, the clear, gel-like substance that fills the back of the eye between the lens and the retina.  The blood from the hemorrhage can obscure vision and prevent ophthalmologists from seeing into the eye to diagnose or treat the cause of the hemorrhage.  The only current treatment options are a watchful waiting period, during which no medical treatment is provided in the hope that the hemorrhage will clear on its own, and an invasive surgical procedure to remove the blood filled vitreous humor from the eye.  Vitrase, when injected into the vitreous humor, causes the vitreous humor to liquefy and promotes clearance of vitreous hemorrhage.  Based on market research we commissioned in February 1999, we believe that approximately one million cases of vitreous hemorrhage occur each year in the United States, Europe and Japan and that approximately half of these cases are candidates for treatment using Vitrase.

Field of Use
The field of use apply to the treatment of the eye.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.